Evaluation of Cell-Free Circulating Plasma DNA in Prostate Cancer.

Abstract

Prostate cancer (PC) is a common health problem. It starts to develop at the age 50 years, the highest level reaching at 60 – 70 years of age. The highest incidence is recorded in US and Canada, followed by European countries, then the Asian population and the lowest incidence is in Arabic populations. Prostate gland secretes prostatic specific antigen (PSA) into the semen and the blood stream. The elevated plasma PSA is occurred in PC, though it is widely used for diagnosis the tumor in patient. However, PSA levels may elevate in the prostatic disease, so it was replaced by the measurement of CF-DNA which has received increasing attention as a cancer biomarker. Therefore, the objective of the study was to evaluate CF-DNA in plasma of PC patients comparing to that found in BPH patients and that detected in healthy men. In addition CF-DNA levels were analyzed in relation to the clinicopathological characteristic of the studied cases. The study was performed at National Cancer Research (NCI) Cairo University and the Urology department Qasr El-Aini between October 2013 to June 2015. The study included 105 Egyptian men classified into three groups. The 50 men with PC, 25 men with BPH were obtained from urology department at Qasr El-Aini Cairo University. The pathological and clinical staging information was obtained from the hospital char